Price
No data yet.
Social Signal Score
Analyst Ratings
20 analystsRevenue
$33.43M+69550.00%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Richard A. Paulson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 228
- Beta
- 0.95
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- -27.43
Financials
Revenue
$33.43M+69550.0%Net Income
$-67.02MEBITDA
$-53.88MFree Cash Flow
$-24.93MEPS (diluted)
$-2.32Shares Outstanding (diluted)
28.94M+1078.7%Operating Expenses
$55.86MCash & Debt
$65.11MRevenue by Segment (annual)
$28.88MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $146.07M | $-196.04M | $-17.93 |
| 2024 | $145.24M | $-76.42M | $-9.41 |
| 2023 | $146.03M | $-143.10M | $-18.79 |
| 2022 | $157.07M | $-165.29M | $-30.28 |
| 2021 | $209.82M | $-124.09M | $-24.75 |
| 2020 | $108.08M | $-196.27M | $-40.87 |
| 2019 | $40.89M | $-199.59M | $-48.32 |
| 2018 | $30.34M | $-178.41M | $-47.11 |
| 2017 | $1.60M | $-128.98M | $-42.15 |
| 2016 | $154.0K | $-109.58M | $-43.80 |
| 2015 | $250.0K | $-118.18M | $-49.80 |
| 2014 | $229.0K | $-75.78M | $-36.45 |
| 2013 | $387.0K | $-33.95M | $-83.85 |
| 2012 | $634.0K | $-15.89M | $-8.01 |
Valuation
KPTIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
40-20.00%Social Signal Score
Mentions (4)
- Newsprnewswire.com·36d ago·Negative
…sNDA Submitted under the Accelerated Approval Pathway; Priority Review Requested – NEWTON, Mass., Aug. 31, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking Accelerated Approval for XPOVIO® (selinexor) in combination with ruxolitinib for patients with myelofibrosis.
View source ↗ - Newszacks.com·54d ago·Neutral
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.32 per share versus the Zacks Consensus Estimate of a loss of $1.53. This compares to a loss of $4.32 per share a year ago.
View source ↗ - Newsprnewswire.com·54d ago·Neutral
Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission – Planned August sNDA Submission for Selinexor in Combination with Ruxolitinib in Myelofibrosis under the Accelerated Approval Pathway Remains on Track – – Planned sNDA for Selinexor plus Ruxolitinib Supported by Phase 3 SENTRY Results Presented at ASCO and EHA and Published in the Journal of Clinical Oncology; Potential to Become the First Approved Combination Therapy
View source ↗ - Newsprnewswire.com·57d ago·Neutral
Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026 -- Conference Call Scheduled for Thursday, August 13, 2026, at 8:00 a.m. ET -- NEWTON, Mass.
View source ↗
Earnings
Mon, Nov 2(in 4 weeks)
Consensus estimate $-1.16 per share
Typical surprise -13.7% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-2.32 vs $-1.37miss
- Thu, May 14$-1.24 vs $-1.45beat
- Thu, Feb 12$-5.68 vs $-2.26miss
- Mon, Nov 3$-3.82 vs $-3.47miss
- Mon, Aug 11$-4.32 vs $-3.80miss
- Mon, May 12$-2.77 vs $-4.21beat
Estimates and results for KPTI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KPTI officers and directors.
- Bought
- —
- Sold
- $404k
0 trades
38 trades
- Abate Kristinsold
- Abate Kristinsold
- Poulton Stuartsold
- Poulton Stuartsold
- Rangwala Reshmasold
- Cheng Sohanya Roshansold
- Abate Kristinsold
- Paulson Richard A.sold
62 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in KPTI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.